Auris Medical completes enrollment of Phase 1b trial of AM-201
Category: #healthcare  By Mateen Dalal  Date: 2019-07-05
  • share
  • Twitter
  • Facebook
  • LinkedIn

Auris Medical completes enrollment of Phase 1b trial of AM-201

AM-201 is an investigating drug being developed for the prevention of antipsychotic drug induced weight gain and somnolence.

Auris Medical Ltd. – a biopharmaceutical company has reportedly completed the enrollment of its phase 1b proof-of-concept trial of AM-201, the antipsychotic-induced weight gain and somnolence prevention investigational drug by the company.

Citing reports, the phase 1b trial of AM-201 is being carried out in Europe and involves 50 healthy volunteers who received either AM-201 or were on placebo simultaneously with olanzapine – an antipsychotic drug for a period of four weeks.

Thomas Meyer, Founder, chairman and CEO at Auris Medical was reportedly quoted stating that the completion of enrollment is an important step in the development of AM-201. Somnolence and excessive weight are the leading side effects of antipsychotic drugs that have a major impact on the patient’s quality of life and well-being, he further claimed.

For the record, AM-201 is a drug being developed for the prevention of antipsychotic drug induced drowsiness and weight gain. Apparently, antipsychotic drugs block the H1 histamine receptors that control the appetite and wakefulness of a person resulting in weight gain and sleepiness as side effects.

Additionally, betahistine - an H1 receptor agonist, counterattacks the side effects of antipsychotics and blocks the H3 histamine auto receptors thus increasing the histamine release and raising betahistine direct effects on H1 receptors. Unlike histamine, it crosses the blood brain barrier and enhances the cerebral and inner ear blood flow, increases the turnover of histamine and releases it in the brain, increases the release of dopamine, acetylcholine and norepinephrine in the brain to generate brain arousal.

About Auris Medical

A Switzerland headquartered biopharmaceutical company aiming at developing medication that addresses unmet medical needs in CNS and neurotological disorders. The company focuses on the development of intranasal betahistine for the prevention of antipsychotic induced side effects like weight gain and somnolence along with the treatment of vertigo (AM-125).

Source Credits : https://ir.aurismedical.com/news-releases/news-release-details/auris-medical-completes-enrollment-phase-1b-proof-concept-trial

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

TikTok owner ByteDance in talks to enter subscription music business
TikTok owner ByteDance in talks to enter subscription music business
By Mateen Dalal

Beijing ByteDance Technology Co Ltd, owner of popular short-video app TikTok has recently announced ...

Kiniksa Pharma releases final phase 2 clinical data for rilonacept
Kiniksa Pharma releases final phase 2 clinical data for rilonacept
By Mateen Dalal

Data renders evidence of clinically improved outcome in recurrent pericarditis   Results we...

U.S. FDA approves FETROJA® (cefiderocol) for treatment of cUTI
U.S. FDA approves FETROJA® (cefiderocol) for treatment of cUTI
By Mateen Dalal

Shionogi & Co., Ltd., a Japan-based pharmaceutical company recently announced approval of drug c...